Celldex Therapeutics, Inc.

CLDX

Explore Our Financial Data > Companies > Celldex Therapeutics, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	CLDX
CIK	0000744218
SIC	2835
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	In Vitro, In Vivo Diagnostic Substances

Contact

Address	53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827
Website	celldex.com
Phone	908-200-7500
CEO	Anthony S. Marucci
Employees	150

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$865,000.00
Pre-Tax Income	$-283.65 million
Net Income	$-283.65 million
Net Income to Common	$-283.65 million
EPS	$-4.27

View All

Balance Sheet

Cash	$35.73 million
Assets	$511.25 million
Liabilities	$55.03 million
Common Equity	$456.23 million
Liabilities & Equity	$511.25 million

View All

Cash Flow Statement

Net Income	$-283.65 million
Cash From Operating Activities	$-222.16 million
Cash From Investing Activities	$238.24 million
Cash From Financing Activities	$2.51 million
Change in Cash	$18.59 million

View All

Calculations

NOPAT	$-216.34 million
EBITDA	$-309.91 million
Price to Earnings	N/A
Price to Book	$5.05
ROE	-48.94%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

[Latest] Global Cholera Vaccine Market Size/Share Worth USD 649 Million by 2035 at a 7.6 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Cholera Vaccine Market size & share revenue was valued at approximately USD 312 Million in 2025 and is expected to reach USD 336 Million in 2026 and is expected to reach around USD 649 Million by 2035, at a CAGR of 7.6 between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Sanofi S.A., Hilleman Laboratories, Bi

Article Link

Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed Signals

Celldex Therapeutics stock overview Celldex Therapeutics (CLDX) has been drawing investor attention after recent trading left the stock at a last close of US$32. With no single headline event driving sentiment, the focus turns to its fundamentals. See our latest analysis for Celldex Therapeutics. Recent moves put Celldex on a softer footing in the very near term, with the 7 day share price return down 5.49%, but a 90 day share price return of 30.08% and 1 year total shareholder return of...

Article Link

Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of -6.88% and -98.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Article Link

Celldex Reports First Quarter Financial Results and Provides Corporate Update

Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for 2027Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively enrolling Phase 1 CDX-622 proof of mechanism study in asthma ongoing2026 expected to deliver multiple key data readouts across the pipelineRaised $345 million in gross proceeds from a follow-o

Article Link

Innoviva (INVA) Tops Q1 Earnings Estimates

Innoviva (INVA) delivered earnings and revenue surprises of +3.53% and -1.83%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Article Link